INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 448m ago
HOUSE PTR47m ago
SEC 13F47m ago
ROBINHOOD CHAIN47m ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Chapman Steven Leonard sold NTRA

Director, CEO AND PRESIDENT · Natera, Inc. · Common Stock

Side
SELL
Value
$1.19M
Shares
2,866
Price
$415.64
Executed
Nov 2, 2026
Disclosed
Nov 4, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 2 executedNov 4, 2026 disclosed

NTRA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
22/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+10 / 25

    $1.2M reported value · 3.2% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+1 / 15

    Routine: 8 prior trades recorded in this security

  • Frequency & clustering+15 / 15

    6 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · NTRA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    13
    FJ
    Fesko JohnPRESIDENT, CHIEF BUS. OFFICER
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$2,717
    7 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    19
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$316K
    760 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    16
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$164K
    410 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    SJ
    Sheena JonathanDirector, CO-FOUNDER
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1,165
    3 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    16
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$213K
    520 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$49K
    120 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    19
    RM
    Rabinowitz MatthewDirector, EXECUTIVE CHAIRMAN
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$293K
    731 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RM
    Rabinowitz MatthewDirector, EXECUTIVE CHAIRMAN
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$6,599
    17 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    16
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$176K
    432 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RD
    Rabinowitz DanielSEC. AND CHIEF LEGAL OFFICER
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$2,717
    7 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    SJ
    Sheena JonathanDirector, CO-FOUNDER
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$44K
    109 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    16
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$166K
    408 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$50K
    120 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$33K
    80 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    BB
    Brophy Michael BurkesCHIEF FINANCIAL OFFICER
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$3,104
    8 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    CL
    Chapman Steven LeonardDirector, CEO AND PRESIDENT
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$8,146
    21 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    19
    CL
    Chapman Steven LeonardDirector, CEO AND PRESIDENT
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$366K
    914 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    16
    BB
    Brophy Michael BurkesCHIEF FINANCIAL OFFICER
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$127K
    317 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$49K
    120 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    16
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$100K
    240 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001711968-26-000030
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 2, 2026
    Published
    Nov 4, 2026
    Ingested by INSIDER
    Nov 5, 02:58 UTC
    Last re-read
    Nov 5, 18:10 UTC

    Extracted facts

    Filer
    Chapman Steven Leonard
    Role
    Director, CEO AND PRESIDENT
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Natera, Inc.
    Ticker
    NTRA
    Shares
    2,866
    Price per share
    $415.64
    Value
    $1,191,224
    Execution date (reported)
    Nov 2, 2026
    Owned after transaction
    87.4K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 2,866
    • Price: $415.64

    = $1,191,224

    What this establishes

    Chapman Steven Leonard filed this Form 4 reporting a open-market sale of NTRA on Nov 2, 2026. It became public on Nov 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, CEO AND PRESIDENT
    Chapman Steven Leonardcik:0001711968
    Issuer
    Natera, Inc.cik:0001604821

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.